Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oflagenix Plus
- Development stage
- Unknown
- Lead developer
- Nilegenix
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Oflagenix Plus is a fixed-dose combination pharmaceutical product developed and marketed by Nilegenix, a generic pharmaceutical company based in India. It is primarily indicated for the treatment of mixed gastrointestinal infections, infectious diarrhea, and dysentery. The formulation typically combines two antimicrobial agents with a probiotic: Ofloxacin, a broad-spectrum fluoroquinolone antibiotic that inhibits bacterial DNA replication by targeting DNA gyrase and topoisomerase IV; Ornidazole, a nitroimidazole derivative that disrupts microbial DNA through the production of reactive intermediates; and *Lactobacillus*, a probiotic used to restore the natural balance of gut flora and prevent antibiotic-associated diarrhea. As a commercial generic formulation, it is approved for clinical use in its target markets.
- Brand names
- Oflagenix Plus
- Other names
- Ofloxacin + Ornidazole + Lactobacillus
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on Oflagenix Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oflagenix Plus.